Neuromuscular diseases: advances in therapy and diagnosis
暂无分享，去创建一个
[1] C. Angelini,et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years , 2012, Journal of Neurology.
[2] G. Callewaert,et al. Mitochondrial dysfunction in familial amyotrophic lateral sclerosis , 2011, Journal of bioenergetics and biomembranes.
[3] D. Ito,et al. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS , 2011, Neurology.
[4] David Heckerman,et al. A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD , 2011, Neuron.
[5] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[6] A. Paetau,et al. FGF-21 as a biomarker for muscle-manifesting mitochondrial respiratory chain deficiencies: a diagnostic study , 2011, The Lancet Neurology.
[7] G. van Ommen,et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.